Nilotinib Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
Conditions:   Metastatic Melanoma;   BRAF Gene Mutation Interventions:   Drug: Nilotinib 100mg;   Drug: Nilotinib 200mg;   Drug: Nilotinib 300mg;   Drug: Nilotinib 400mg;   Drug: Dabrafenib;   Drug: Trametinib Sponsor:   Peng Wang, MD PhD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2021 Category: Research Source Type: clinical trials